History

The ambitious pursuit of innovation

About Us History

Before the world even imagined that 4 million drug-eluting stents would be available in 36 countries around the world, the founders of MicroPort® were imagining how they would impact the lives of people through technology. Their belief was that these medical technologies must be accessible to everyone.

Relentless innovation has inspired promising product development and initiated strategic investments in emerging scientific platforms. Today, we see a promising path forward, one that addresses the most challenging healthcare issues, while allowing us to explore the ways to accelerate and broaden access to medical technology innovation.

MILESTONES 2019

SoSuperior™ Medial Stability Total Knee Replacement System and Aspiration™ Medial Pivot Total Knee Replacement System gained approval in China.

MicroPort® Obtained CE Mark for Firehawk Liberty™, a New Generation Rapamycin Target Eluting Coronary Stent System.

The 24 months results of the Firehawk® TARGET AC trial were announced in EuroPCR 2019, and would be published in the Journal of the American College of Cardiology (JACC).

Every 8 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

MicroPort® was awarded "2018 Responsible Brand" at the 8th China Charity Festival.

The Group’s Firehawk® and Rega® Family Implantable Pacemakers made the list of Health China (2018) • Top 10 Medical Devices.

The Group’s Panoramic Endoscope Design won iF DESIGN AWARD 2019.

The Group won Shanghai Municipality Gold Quality Prize.

The Group won the title of 2018 Shanghai Municipality Quality Benchmark Enterprise.

Annual report

Download

MILESTONES 2018

Firehawk® clinical data from the Target AC European clinical trial has been accepted for publication in the prestigious medical journal The Lancet.

Tubridge® Vascular Reconstruction Device was launched.

Firehawk® and Firebird2® gained regulatory approval in Taiwan.

First implantation of Rega® Family Implantable Pacemakers.

Global aggregated implantations of coronary artery stent system, artificial joint implants and pacemakers reached 4.5 million, 1.1 million and 1 million respectively.

MicroPort® CRM global headquarter was established in Clamart, France.

MicroPort Orthopedics (Suzhou) Co., Ltd. was established.

Every 12 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

The Group was one of the first winners of Shanghai Brand certificate.

The Group’s “微创®” and “MicroPort®” trademarks were granted entry into the List of the First Batch of Major Protected Trademarks of Shanghai Municipality.

Annual report

Download

MILESTONES 2017

Proposed to acquire the cardiac rhythm management business of LivaNova for $190 million in cash.

AAA/TAA stent graft series product critical technical development and large-scale industrialization won State Science and Technology Award.

Rega® Family Implantable Pacemakers and Firefighter™ PTCA Balloon Catheters received CFDA approval.

The data of Firehawk® TARGET AC clinical trial showed the 3-month stent strut cover rate was of 99.9%, 5-year follow-up data of TARGET I RCT showed stent thrombus rate was 0.

Medial-Pivot Knee arthroplasty system demonstrated high survivorship (98.8%) and patient satisfaction (95%) in a 17-year follow-up study.

Firesorb® pivotal study FUTURE II trial completed first enrollment.

MicroPort® CardioFlow brought in strategic investors.

MicroPort® EP quoted on NEEQ.

MicroPort Urocare Co., Ltd. established, marking the company's official entry in urology and gynecology sectors.

MicroPort® Jiaxing park established.

Acquired Brazil distributors to implement localized management on the Brazil market.

AWARDS & HONORS

MicroPort® was awarded Five Star Credit Enterprise.

MicroPort® was awarded Corporate Social Responsibility Award of Shanghai Pudong District.

The Group’s project of Development and Large-scale Industrialization of Key Technologies for Aortic Stent Graft Series Products won the Second Prize of the National Science and Technology Progress Awards.

The Group was awarded the title of China Import & Export Quality Trustworthy Enterprise in 2017.

The Group awarded the title of China Innovation Medical Device Enterprise in 2017.

The Group was a holder of the Shanghai Famous Brand title for 12 consecutive years.

The Group was awarded the title of Shanghai Municipality Excellent Innovation Pilot Enterprise in 2017.

The Group was awarded the title of Pudong New Area International Trade Brand Model Enterprise.

Annual report

Download

MILESTONES 2016

New Technology and Clinical Application of Minimally Invasive Cardiac Surgery project won the State Science and Technology Advancement Award.

Columbus® 3D EP Navigation System received CFDA approval.

MicroPort Scientific India Private Ltd. Established.

MicroPort® Suzhou park established.

Annual sales exceeded 3 billion HKD.

Every 15 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

"New Technology and Clinical Application of Minimally Invasive Cardiac Surgery" Project Won the Second Prize of State Science and Technology Progress Award.

MicroPort® was listed among "2016 National Technology Innovation Model Enterprises."

MicroPort® was granted the Annual PMO (Project Management Office) Award and Project Management Award Finalist by PMI (Project Management Institute).

Annual report

Download

MILESTONES 2015

MicroPort® Innovation Platform won State Science and Technology Advancement Award.

Firehawk® Rapamycin Target Eluting Coronary Stent received CE mark.

EVOLUTION® medial-pivot knee system received CFDA approval.

MicroPort Sorin CRM (Shanghai) Co., Ltd. launched China's first domestic pacemaker production line.

MicroPort Suzhou OrthoRecon Co., Ltd. and MicroPort Suzhou Orthopedic Instruments Co., Ltd. were established in Suzhou Industrial Zone.

MicroPort Surgical Robotics Co., Ltd. and MicroPort Online Co., Ltd. were established.

Every 18 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

"Key technology and industrialization platform for minimally invasive interventional and implantable medical devices" project won prestigious class II prize of State Science and Technology Advancement Award.

Shanghai MicroPort EP MedTech Co., Ltd. received "Shanghai Hi-Tech Enterprise" honor.

Annual report

Download

MILESTONES 2014

Firehawk® rapamycin target eluting coronary stent system received CFDA approval.

WILLIS® clinical application project won State Science and Technology Advancement Award.

Signed joint venture agreement with Sorin Group for China's cardiac rhythm management business.

Acquired drug eluting stent related assets and intellectual properties from Cordis.

Moved into new headquarter on at 1601 Zhangdong Rd, Zhangjiang Hi-tech Park.

Annual sales exceeded 2 billion RMB.

Every 20 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

WILLIS® clinical application project won prestigious class II prize of State Science and Technology Advancement award.

WILLIS® intracranial stent graft system received 2013 Shanghai new product patent certificate.

"微创®" and "MicroPort®" trademarks received "China Famous Trademark" honor.

Annual report

Download

MILESTONES 2013

MicroPort® Orthopedics Global Headquarter was established in Arlington, TX, USA.

Globalization Strategy Implemented.

Every 20 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

Four projects were listed in Shanghai Science and Technology Committee's science and technology support program.

Annual report

Download

MILESTONES 2012

Initiated “10+5” Operating Model.

Shanghai MicroPort® NeuroTech Co., Ltd., Shanghai MicroPort Endovascular MedTech Co., Ltd. and MicroPort Surgical (Shanghai) Co., Ltd. were established.

Acquired D-Pulse Medical (Beijing) Co., Ltd. and Dongguan Kewei Medical Instrument Co., Ltd.

Every 20 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

WILLIS® clinical application project won Ministry of Education's Science and Technology Progress Award.

"R&D of Domestic implantable dual chamber pacemaker system" was selected for Shanghai Science and Technology Committee’s science and technology support program.

"Drug eluting stent" patent won 14th "China Patent Excellence Award".

Received "Top Ten Business Award" from Shanghai Biopharmaceutics Industry Association.

2012 national enterprise technology center's innovation capacity building project was officially approved.

Annual report

Download

MILESTONES 2011

MicroPort Medical (Jiaxing) Co., Ltd. was established.

Undertook national R&D projects accumulating to more than 100 million RMB.

Shanghai MicroPort Orthopedics Co., Ltd. acquired Suzhou Best Co., Ltd.

Every 18 seconds, a MicroPort® product was used across the world.

AWARDS & HONORS

"Cerebral vascular interventional medical device development and clinical research" project was selected for "12th Five year plan" of national science and technology support program.

APOLLO was selected as a national key new product project.

Received China Torch Program's key high-tech enterprise certification.

Annual report

Download

MILESTONES 2010

MicroPort Scientific Corporation listed on Hong Kong Stock Exchange (00853.HK).

Annual sales exceeded 100 million USD.

Shanghai MicroPort EP MedTech Co., Ltd. was established.

AWARDS & HONORS

"R&D and industrialization of chronic disease treatment devices" was listed as a Shanghai bio-pharmaceutics industrialization projects.

Received national enterprise technology center certification.

Annual report

Download

MILESTONES 2009

Firebird2™ coronary drug-eluting stent system received registration approval from SFDA.

Shanghai MicroPort Orthopedics Co., Ltd. was established.

AWARDS & HONORS

Drug eluting stent system received innovation product certificate from Ministry of Science and Technology.

MILESTONES 2008

Shanghai MicroPort Lifesciences Co., Ltd. was established, officially entered diabetes business; diversified business strategy implemented.

Began experimental implementation of "Vertical Integration & Horizontal Connection" management model.

AWARDS & HONORS

Awarded title of "Shanghai technology small giant enterprise" by two Shanghai municipal government agencies.

Firebird2™ was awarded Shanghai key new product certificate by Shanghai Science and Technology Committee.

MILESTONES 2007

Firebird™ coronary drug eluting stent system won State Science and Technology Advancement Award.

AWARDS & HONORS

"Drug eluting stent" was awarded class II prize of State Science and Technology Advancement award.

MILESTONES 2006

Hercule® Thoracic Stent-Graft System received SFDA approval.

Coronary drug eluting stent implants reached over 100,000 units.

MILESTONES 2005

Aegis Bifurcated Stent-Graft System was named National key new product.

Annual sales exceeded 100 million RMB.

MILESTONES 2004

Firebird™ drug eluting stent system received SFDA approval.

Mustang™ coronary stent system received CE mark.

AWARDS & HONORS

Coronary stent system was selected as a national key new product project.

MILESTONES 2003

Officially entered Japan market with PTCA Balloon dilatation catheters.

MILESTONES 2002

Received major funding from National Development and Reform Commission.

MILESTONES 2001

Moved into new headquarters at 501 Newton Road, Zhangjiang Hi-Tech Park.

Received "Shanghai Hi-Tech Enterprise" honor and business became profitable.

AWARDS & HONORS

Awarded title of "high-tech enterprise" by certifications from four Shanghai municipal government agencies.

MILESTONES 2000

Mustang™ bare metal stent received SFDA approval.

MILESTONES 1999

PTCA balloon dilatation catheter received SFDA approval, very first sale made.

MILESTONES 1998

Founded on May 15, 1998 at an incubation center in Zhangjiang Hi-Tech Park, Shanghai.